Christopher Hite - Net Worth and Insider Trading

Christopher Hite Net Worth

The estimated net worth of Christopher Hite is at least $23 Million dollars as of 2026-09-11. Christopher Hite is the EVP & Chairman, Partnering of Royalty Pharma PLC and owns about 393,601 shares of Royalty Pharma PLC (RPRX) stock worth over $23 Million. Details can be seen in Christopher Hite's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher Hite has not made any transactions after 2026-08-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Christopher Hite

To

Are these stocks worth buying? — GuruFocus analysis for each holding

Christopher Hite Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christopher Hite owns 4 companies in total, including Royalty Pharma PLC (RPRX) , Acceleron Pharma Inc (XLRN) , and Vera Therapeutics Inc (VERA) among others .

Click here to see the complete history of Christopher Hite’s form 4 insider trades.

Insider Ownership Summary of Christopher Hite

Ticker Company Transaction Date Type of Owner
RPRX Royalty Pharma PLC 2026-08-18 EVP & Vice Chairman
XLRN Acceleron Pharma Inc 2020-06-04 director
VERA Vera Therapeutics Inc 2026-03-05 director
LIMIT LIMIT 2026-04-16 director

Christopher Hite Latest Holdings Summary

Christopher Hite currently owns a total of 1 stock. Christopher Hite owns 393,601 shares of Royalty Pharma PLC (RPRX) as of August 18, 2026, with a value of $23 Million.

Latest Holdings of Christopher Hite

Ticker Company Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RPRX Royalty Pharma PLC 2026-08-18 393,601 58.69 23,100,443

Holding Weightings of Christopher Hite


Christopher Hite Form 4 Trading Tracker

According to the SEC Form 4 filings, Christopher Hite has made a total of 3 transactions in Royalty Pharma PLC (RPRX) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Royalty Pharma PLC is the sale of 100,000 shares on August 18, 2026, which brought Christopher Hite around $6 Million.

Insider Trading History of Christopher Hite

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christopher Hite Trading Performance

GuruFocus tracks the stock performance after each of Christopher Hite's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Christopher Hite is -17.52%. GuruFocus also compares Christopher Hite's trading performance to market benchmark return within the same time period. The performance of stocks bought by Christopher Hite within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Christopher Hite's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Christopher Hite

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -13.18 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -16.69 LIMIT LIMIT LIMIT LIMIT LIMIT

Get the full picture on these stocks
See GF Score, valuation, financials, and warning signs for every stock Christopher Hite owns.
View RPRX Analysis

Christopher Hite Ownership Network

Ownership Network List of Christopher Hite

No Data

Ownership Network Relation of Christopher Hite

Insider Network Chart


Christopher Hite Owned Company Details

What does Royalty Pharma PLC do?

Who are the key executives at Royalty Pharma PLC?

Christopher Hite is the EVP & Vice Chairman of Royalty Pharma PLC. Other key executives at Royalty Pharma PLC include EVP & CFO Terrance P. Coyne , EVP & Research & Investments Marshall Urist , and EVP & Investments & GC Arthur Richard Mcgivern .

Royalty Pharma PLC (RPRX) Insider Trades Summary

Over the past 18 months, Christopher Hite made 3 insider transaction in Royalty Pharma PLC (RPRX) with a net sale of 380,000. Other recent insider transactions involving Royalty Pharma PLC (RPRX) include a net sale of 910,401 shares made by Terrance P. Coyne , a net sale of 288,716 shares made by Marshall Urist , and a net sale of 355,426 shares made by George W. Lloyd .

In summary, during the past 3 months, insiders sold 409,199 shares of Royalty Pharma PLC (RPRX) in total and bought 0 shares, with a net sale of 409,199 shares. During the past 18 months, 1,971,088 shares of Royalty Pharma PLC (RPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,971,088 shares.

Royalty Pharma PLC (RPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Royalty Pharma PLC Insider Transactions

No Available Data

Christopher Hite Mailing Address

Above is the net worth, insider trading, and ownership report for Christopher Hite. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Christopher Hite's mailing address is: Cambridge Ma 02139.